What's Happening?
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's Saphnelo (anifrolumab) for self-administration as a once-weekly autoinjector, known as the Saphnelo Pen, for adult patients with systemic lupus erythematosus (SLE). This approval is based
on the results from the Phase III TULIP-SC trial, which demonstrated a significant reduction in disease activity in patients with moderate to severe SLE when Saphnelo was administered subcutaneously, compared to a placebo. The safety profile of the subcutaneous administration was consistent with the known clinical profile of Saphnelo when given as an intravenous infusion. The approval is seen as a significant advancement in making the treatment more accessible and convenient for patients.
Why It's Important?
This development is crucial as it provides patients with SLE, a serious autoimmune condition, more flexibility and convenience in managing their treatment. The ability to self-administer the medication at home can improve adherence to treatment regimens and potentially enhance patient outcomes. SLE is a leading cause of death among young women in the U.S., particularly affecting Asian, Black, and Hispanic populations. The approval of the Saphnelo Pen aligns with recent clinical guidelines that emphasize reducing the use of oral corticosteroids, which are associated with adverse effects, and focusing on achieving remission or low disease activity.
What's Next?
Following the FDA approval, AstraZeneca plans to expand the availability of the Saphnelo Pen to more patients in the U.S. and potentially other markets. The subcutaneous administration of Saphnelo is already approved in the EU and Japan and is under regulatory review in several other countries. AstraZeneca will continue to promote the benefits of Saphnelo, aiming to reach more patients globally. The company will also pay royalties to Bristol-Myers Squibb for U.S. sales, as per their agreement.
